Elucid Valuation, Funding & Investors

Elucid is valued at $256M as of November 2023.

Last Elucid valuation

$256M

Series C · Nov 2023

Last Elucid funding round

$37M

Series D · Oct 2025

Cumulative funding Elucid raised

$159M

across 6 funding rounds

Key investors in Elucid

  • IAG Capital Partners
  • BlueStone Venture Partners
  • MedTex Ventures
  • Sand Hill Angels
  • Aphelion Capital
  • Bioverge

Elucid Overview

About Elucid

Elucid is a Boston-based developer of AI-powered cardiovascular imaging software. Its FDA-cleared ElucidVivo analyzes coronary CT angiography scans to quantify plaque volume, composition, and vulnerability risks for heart attack or stroke. Validated against histology in over 1,000 patients, the tool guides treatment decisions like stenting or statins. Elucid partners with Siemens Healthineers and provides services to pharma firms including Pfizer.


Founded

2013

HQ

United StatesBoston, MA

Website

elucid.com

Status

Privately held

Customer focus

B2B

Revenue model

Subscription

Valuation

$256M (Nov 2023)

Elucid Valuation

Elucid is currently valued at $256M, based on its Series C in November 2023.

The $80M round was led by Elevage Medical Technologies.

Elucid's valuation has grown 2.1x from $121M at its Series B in June 2022 to $256M in November 2023, across 2 priced rounds.

Elucid valuation by funding round

Elucid valuation by funding round
DateStageValuation
Nov 2023Series C$256M
Jun 2022Series B$121M

Elucid Funding History

Elucid has raised a total of $159M across 6 funding rounds.

Elucid's first fundraising round was a $1M seed round in January 2016. The most recent completed round was a $37M Series D in October 2025.

Elucid funding rounds

Elucid funding rounds
DateStageInvestorsRaisedValuationDeal Summary
Oct 2025Series D-$37M-Elucid is a Boston-based medical technology company developing AI-powered imaging analysis software for non-invasive assessment of cardiovascular disease risk, quantifying atherosclerotic plaque characteristics like Lipid Rich Necrotic Core compared to histopathology, and deriving fractional flow reserve (FFRct) from CTA analysis to optimize physician treatment decisions and enable precision medicine. The company raised $36.5M on October 22, 2025, as an initial filing from an offering of $80M, following prior rounds including a Series C of $80M on November 9, 2023 led by Elevage Medical Technologies (bringing total funding to $121M then), with overall funding reported variably as $115.37M to $163.2M across 4-6 rounds from investors like IAG Capital Partners, MedTex Ventures, Bluestone Venture Partners, and others. This latest round supports ongoing commercialization, clinical research, and expansion of its diagnostic tools to combat heart disease. Traction includes bolstered leadership with board additions like Dr. Evan Melrose and Dr. Kelly Huang from Elevage, and Scott Huennekens as executive chairman, alongside growth to approximately 72-127 employees. The Series C - II or extension builds on momentum from clinical validations and market needs for AI cardiovascular software. Competitive context positions Elucid as a leader in histology-validated, cost-effective vascular imaging, aiming to reduce heart attack and stroke deaths through improved diagnosis and management.
Nov 2023Series CElevage Medical Technologies (lead)$80M$256MElucid Bioimaging, Inc., a Boston-based medical technology company, develops AI-powered imaging analysis software to assess cardiovascular disease, providing physicians with non-invasive diagnostic tools like PlaqueIQ to evaluate plaque composition, coronary blockages, and ischemia risk, aiming to bring precision care from oncology to cardiology. On November 9, 2023, Elucid raised $80 million in a Series C funding round led by Elevage Medical Technologies, with participation from industry strategics and existing investors, bringing total funding to $121 million since inception. The funds are designated to drive commercialization, expand clinical research and development, and accelerate market penetration for its cardiovascular diagnostic software amid growing demand for AI solutions in heart disease management. Elevage Medical Technologies, a platform by Patient Square Capital, supports medical device and technology firms through capital and operational aid; its CEO Dr. Evan Melrose and Senior Advisor Dr. Kelly Huang joined Elucid's board post-investment, alongside executive chairman Scott Huennekens. Elucid's leadership enhancements and prior momentum position it to reduce heart attack and stroke deaths via improved diagnosis and treatment outcomes, competing in the arterial analysis software space against firms like HeartFlow. Forge Global reports a post-money valuation of $256.49 million for this Series C round, with a price per share of $1.94, though primary announcements do not disclose valuation details. No sources provide explicit revenue, ARR, or EBITDA metrics near the November 2023 round using terms like 'revenue' or 'ARR'; secondary estimates exist but lack verification from press releases. Elucid continues advancing indications like FFRCT derived from its technology while ramping commercial efforts.
Jun 2022Series BBlueStone Venture Partners; IAG Capital Partners; MedTex Ventures; Bold Brain Ventures; Biovision Ventures; Aphelion Capital$27M$121MElucid is a medical technology company developing AI-powered imaging analysis software to assess cardiovascular disease risk through non-invasive diagnostic tools. The company raised $23 million in a Series B-1 round on June 23, 2022, from investors including Biovision Ventures, Bluestone Venture Partners, Bold Brain Ventures, IAG Capital Partners, and Medtex Ventures, achieving a post-money valuation of $120.62 million at a share price of $1.94. This round contributed to Elucid's ongoing funding trajectory, with prior Series A rounds in 2021 totaling around $14 million across multiple tranches at approximately $58 million valuation. The 2022 Series B funding supported Elucid's expansion in commercialization and clinical development amid growing demand for AI-driven cardiovascular diagnostics. Elucid continued fundraising post-2022, securing an $80 million Series C on November 9, 2023, led by Elevage Medical Technologies, bringing total funding to $121 million. This later round emphasized commercialization acceleration and board additions like Dr. Evan Melrose.
May 2021Series AGlobal Health Impact Fund (lead); MedTex Ventures (lead); Bioverge; BlueStone Venture Partners; Angel Physicians Fund; IAG Capital Partners; Checkmate Capital; Wolverine Venture Fund; Sand Hill Angels; Willamette Valley Capital$10M--
Aug 2016Seed-$4M--
Jan 2016Seed-$1M--

Who has invested in Elucid?

14 investors have backed Elucid across its funding rounds, including IAG Capital Partners, BlueStone Venture Partners, MedTex Ventures, Sand Hill Angels, Aphelion Capital and Bioverge.

Lead investors include Elevage Medical Technologies, Global Health Impact Fund and MedTex Ventures.


Elucid Investors

Investors in Elucid by funding rounds participated
InvestorHQRoundsRoleFirst check
BlueStone Venture PartnersUnited StatesTucson, AZ2ParticipantMay 2021
IAG Capital PartnersUnited StatesCharleston, SC2ParticipantMay 2021
MedTex VenturesUnited StatesNorwalk, CT2LeadMay 2021
BiovergeUnited StatesSan Francisco, CA1ParticipantMay 2021
Angel Physicians FundUnited StatesCincinnati, OH1ParticipantMay 2021
Checkmate CapitalUnited StatesLos Angeles, CA1ParticipantMay 2021
Wolverine Venture FundUnited StatesAnn Arbor, MI1ParticipantMay 2021
Sand Hill AngelsUnited StatesSan Francisco, CA1ParticipantMay 2021
Willamette Valley CapitalUnited StatesSan Francisco, CA1ParticipantMay 2021
Bold Brain VenturesUnited StatesPittsburgh, PA1ParticipantJun 2022
Global Health Impact FundUnited StatesSan Francisco, CA1LeadMay 2021
Biovision VenturesLuxembourgLuxembourg1ParticipantJun 2022

This data is available for Pro users. Sign up to see all 14 Elucid investors.

Start Free Trial

Benchmark 350K+ Funding Rounds and Disclosed VC Valuation Multiples

Sign up to see data on 350K+ funding rounds and disclosed revenue and EBITDA valuation multiples, from seed, through growth stage, to pre-IPO.

Start Free Trial

Elucid Competitors

Elucid competitors include listed companies like Detection Technology and Atrys Health, and private ones like PhAST Diagnostics, Qure AI, Omniscient Neurotechnology and Koning.

Public and private companies comparable to Elucid
CompanyHQStatusRevenueEBITDAValuationRevenue Multiple
Detection TechnologyFinlandFinlandPublicly listed$116M$11M$128M0.9x
Atrys HealthSpainSpainPublicly listed$162M($12M)$245M2.1x
PhAST DiagnosticsUnited StatesUnited StatesPrivate--$242M-
Qure AIIndiaMumbaiPrivate$19M-$240M12.6x
Omniscient NeurotechnologyAustraliaSydneyPrivate--$284M-
KoningUnited StatesNorcross, GAPrivate--$230M-

Elucid Public Comps

Elucid is still privately-owned, but its public comps include Atrys Health, Infinitt Healthcare, Healius, Biodesix, Exagen, Bioneer, Lucid Diagnostics, EKF Diagnostics, NIOX Group and Australian Clinical Labs.

Last FYEV/RevenueEV/EBITDA
RevenueEBITDALast FYLTM2027ELast FYLTM2027E
Atrys Health$162M($12M)2.3x2.1x(30.2x)14.9x
Infinitt Healthcare$75M$27M1.1x-3.2x-
Healius$956M($215M)0.9x0.9x(4.1x)4.8x
Biodesix$88M($22M)3.9x3.3x(15.7x)(30.2x)
Exagen$67M($13M)2.9x2.7x(14.4x)(27.4x)
Bioneer$240M$16M0.8x-12.5x-
Lucid Diagnostics$5M($58M)29.9x24.0x(2.4x)(2.8x)
EKF Diagnostics$69M$17M1.9x1.8x7.8x7.3x

This data is available for Pro users. Sign up to see all Elucid competitors and their valuation data.

Start Free Trial

Common questions about Elucid

When was Elucid founded?Elucid was founded in 2013.
Where is Elucid headquartered?Elucid is headquartered in Boston, MA, United States.
Is Elucid publicly listed?No, Elucid is a private, VC-backed company.
What is Elucid's valuation?Elucid was last valued at $256M in its Series C in November 2023.
How much funding has Elucid raised?Elucid has raised $159M across 6 funding rounds.
What was Elucid's last funding round?Elucid's last funding round was a $37M Series D in October 2025.
Who are Elucid's investors?Elucid's investors include BlueStone Venture Partners, IAG Capital Partners, MedTex Ventures, Bioverge, Angel Physicians Fund, Checkmate Capital, Wolverine Venture Fund, Sand Hill Angels, Willamette Valley Capital, Bold Brain Ventures and 4 others.
Which companies are comparable to Elucid?Companies comparable to Elucid include Detection Technology, Atrys Health, PhAST Diagnostics, Qure AI, Omniscient Neurotechnology and Koning.

See companies similar to Elucid

Start Your
Free Trial Today

Try Multiples for free for 3 days. Got questions or need a demo? Schedule a call with us below.

Start Trial